Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,117 across all filing types
Latest filing 2024-10-17 Regulatory Filings
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Annual Report to shareholders 98 pages 7.5MB
Regulatory Filings
2024-10-17 English
2024 Notice of Annual General Meeting and shareholder pack 20 pages 1.1MB
AGM Information Classification · 100% confidence The document is a detailed notice and related materials for the 2024 Annual General Meeting (AGM) of Mayne Pharma Group Limited. It includes the Notice of Meeting, proxy form, letter from the Chair, details on how to participate in the AGM, the agenda including consideration of statutory reports, re-election of directors, adoption of remuneration report, and other shareholder resolutions. The document is dated October 18, 2024, and the AGM is scheduled for November 21, 2024. The content is focused on informing shareholders about the AGM and facilitating their participation and voting. It does not contain the actual annual report or financial statements themselves, but rather the meeting notice and related proxy materials. This fits the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM. The document length (15,000 characters) and detailed content confirm it is not a brief announcement or a simple report publication notice. Therefore, the correct classification is AGM Information (AGM-R).
2024-10-17 English
Notification of cessation of securities - MYX 4 pages 14.8KB
Transaction in Own Shares Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the lapse of performance rights securities for Mayne Pharma Group Limited. It provides specific information about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. The document is a formal announcement related to changes in the company's securities, specifically the cessation of certain equity securities. This fits the category of a Major Shareholding Notification or related securities change announcement. However, since it concerns cessation of securities (lapse of performance rights) and changes in issued capital, it aligns best with the 'Transaction in Own Shares' category, which covers share repurchase, issuance, or changes in securities held by the company. The document is short (3926 characters) and is a direct announcement, not a report or certification. Therefore, the most appropriate classification is POS (Transaction in Own Shares).
2024-09-12 English
Notification regarding unquoted securities - MYX 6 pages 18.8KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of unquoted securities under an employee incentive scheme by Mayne Pharma Group Limited. It includes specifics such as the number of securities issued, dates, and mentions compliance with ASX listing rules. This is a formal announcement of a share issue event, specifically related to employee incentive securities, and not a full financial report or earnings release. The content aligns with announcements about new share issues or capital changes. Therefore, the document fits the category of Share Issue/Capital Change (SHA). The document length and detail confirm it is not a brief notice or a report publication announcement but a substantive notification of capital change.
2024-09-12 English
Notification regarding unquoted securities - MYX 6 pages 18.5KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of unquoted securities under an employee incentive scheme by Mayne Pharma Group Limited. It includes specifics such as the number of securities issued, dates, and compliance with ASX listing rules. This type of document is a formal announcement regarding new securities issued by the company, specifically related to share issues or capital changes. It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about share issuance. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length (6321 characters) and content confirm it is a full notification rather than a brief report publication announcement or a regulatory filing fallback.
2024-09-12 English
Notification regarding unquoted securities - MYX 6 pages 19.0KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of unquoted securities under an employee incentive scheme by Mayne Pharma Group Limited. It includes specifics such as the number of securities issued, issue dates, and information about key management personnel receiving securities. The document is a formal notification to the ASX about a securities issue, which aligns with announcements regarding new share issues or capital changes. It is not a full financial report, earnings release, or management discussion, but rather a regulatory announcement about capital changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and content confirm it is not merely a brief announcement or a certification, but a detailed notification of a capital change event.
2024-09-12 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.